Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: BRD4

Gene summary for BRD4

Gene summary.

Gene information	Species	Human
	Gene symbol	BRD4
	Gene ID	23476
	Gene name	bromodomain containing 4
	Gene Alias	CAP
	Cytomap	19p13.12
	Gene Type	protein-coding
	GO ID	GO:0000082
	UniProtAcc	A0A024R7H8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23476	BRD4	CA_HPV_1	Human	Cervix	CC	2.43e-04	6.42e-02	0.0264
23476	BRD4	CCI_2	Human	Cervix	CC	2.96e-07	6.52e-01	0.5249
23476	BRD4	CCI_3	Human	Cervix	CC	1.34e-03	5.92e-01	0.516
23476	BRD4	sample1	Human	Cervix	CC	2.68e-02	4.60e-01	0.0959
23476	BRD4	sample3	Human	Cervix	CC	2.31e-02	7.18e-02	0.1387
23476	BRD4	T1	Human	Cervix	CC	2.24e-08	5.04e-01	0.0918
23476	BRD4	HTA11_3410_2000001011	Human	Colorectum	AD	3.09e-05	-3.27e-01	0.0155
23476	BRD4	HTA11_7696_3000711011	Human	Colorectum	AD	1.49e-10	5.38e-01	0.0674
23476	BRD4	A015-C-203	Human	Colorectum	FAP	1.01e-18	-1.24e-01	-0.1294
23476	BRD4	A015-C-204	Human	Colorectum	FAP	8.49e-03	-1.08e-01	-0.0228
23476	BRD4	A002-C-201	Human	Colorectum	FAP	2.74e-08	8.28e-02	0.0324
23476	BRD4	A001-C-119	Human	Colorectum	FAP	1.02e-03	4.82e-02	-0.1557
23476	BRD4	A001-C-108	Human	Colorectum	FAP	4.48e-10	-2.12e-02	-0.0272
23476	BRD4	A002-C-205	Human	Colorectum	FAP	1.53e-18	-1.13e-01	-0.1236
23476	BRD4	A015-C-005	Human	Colorectum	FAP	2.41e-02	-1.43e-01	-0.0336
23476	BRD4	A015-C-006	Human	Colorectum	FAP	1.02e-12	-1.92e-02	-0.0994
23476	BRD4	A015-C-106	Human	Colorectum	FAP	1.02e-06	-4.20e-02	-0.0511
23476	BRD4	A002-C-114	Human	Colorectum	FAP	3.29e-15	-2.09e-01	-0.1561
23476	BRD4	A015-C-104	Human	Colorectum	FAP	2.39e-20	-4.64e-02	-0.1899
23476	BRD4	A001-C-014	Human	Colorectum	FAP	1.61e-05	-8.49e-02	0.0135

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00447725	Cervix	CC	mitotic cell cycle phase transition	89/2311	424/18723	2.70e-07	1.12e-05	89
GO:00457876	Cervix	CC	positive regulation of cell cycle	66/2311	313/18723	7.78e-06	1.81e-04	66
GO:00000824	Cervix	CC	G1/S transition of mitotic cell cycle	49/2311	214/18723	1.16e-05	2.48e-04	49
GO:00073466	Cervix	CC	regulation of mitotic cell cycle	88/2311	457/18723	1.26e-05	2.60e-04	88
GO:19019903	Cervix	CC	regulation of mitotic cell cycle phase transition	63/2311	299/18723	1.27e-05	2.60e-04	63
GO:00448434	Cervix	CC	cell cycle G1/S phase transition	53/2311	241/18723	1.76e-05	3.32e-04	53
GO:00459316	Cervix	CC	positive regulation of mitotic cell cycle	32/2311	121/18723	1.88e-05	3.47e-04	32
GO:00507273	Cervix	CC	regulation of inflammatory response	75/2311	386/18723	3.95e-05	6.18e-04	75
GO:19019922	Cervix	CC	positive regulation of mitotic cell cycle phase transition	26/2311	93/18723	3.97e-05	6.18e-04	26
GO:00431228	Cervix	CC	regulation of I-kappaB kinase/NF-kappaB signaling	53/2311	249/18723	4.50e-05	6.87e-04	53
GO:00063257	Cervix	CC	chromatin organization	78/2311	409/18723	5.40e-05	8.02e-04	78
GO:00900685	Cervix	CC	positive regulation of cell cycle process	50/2311	236/18723	8.25e-05	1.11e-03	50
GO:19019873	Cervix	CC	regulation of cell cycle phase transition	74/2311	390/18723	9.80e-05	1.27e-03	74
GO:00104525	Cervix	CC	histone H3-K36 methylation	8/2311	15/18723	1.53e-04	1.85e-03	8
GO:00165705	Cervix	CC	histone modification	84/2311	463/18723	1.70e-04	2.01e-03	84
GO:00072497	Cervix	CC	I-kappaB kinase/NF-kappaB signaling	56/2311	281/18723	1.81e-04	2.12e-03	56
GO:19019892	Cervix	CC	positive regulation of cell cycle phase transition	28/2311	115/18723	2.82e-04	3.07e-03	28
GO:1902751	Cervix	CC	positive regulation of cell cycle G2/M phase transition	11/2311	30/18723	5.71e-04	5.45e-03	11
GO:00349685	Cervix	CC	histone lysine methylation	27/2311	115/18723	6.61e-04	6.09e-03	27
GO:00310565	Cervix	CC	regulation of histone modification	33/2311	152/18723	7.97e-04	7.00e-03	33

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

BRD4

SNV

Missense_Mutation

novel

c.2808N>T

p.Gln936His

p.Q936H

O60885

protein_coding

tolerated(0.08)

benign(0)

TCGA-A2-A4RY-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

taxotere

BRD4

SNV

Missense_Mutation

rs761158744

c.1638N>C

p.Lys546Asn

p.K546N

O60885

protein_coding

tolerated(0.1)

probably_damaging(0.922)

TCGA-A7-A26H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

BRD4

SNV

Missense_Mutation

rs369254108

c.44N>T

p.Pro15Leu

p.P15L

O60885

protein_coding

deleterious_low_confidence(0.02)

possibly_damaging(0.656)

TCGA-AR-A1AX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

BRD4

SNV

Missense_Mutation

novel

c.1801T>A

p.Ser601Thr

p.S601T

O60885

protein_coding

deleterious(0.03)

benign(0.262)

TCGA-E9-A1NC-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

BRD4

SNV

Missense_Mutation

c.3219N>C

p.Met1073Ile

p.M1073I

O60885

protein_coding

tolerated_low_confidence(0.08)

benign(0)

TCGA-EW-A1PB-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

BRD4

insertion

In_Frame_Ins

novel

c.1798_1799insTCTGGGGCCTCTCTGCACCTTGTTGCCTGCAGCTGTGTTCTA

p.Glu600delinsValTrpGlyLeuSerAlaProCysCysLeuGlnLeuCysSerLys

p.E600delinsVWGLSAPCCLQLCSK

O60885

protein_coding

TCGA-A8-A095-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

BRD4

insertion

Frame_Shift_Ins

novel

c.3504_3505insACCAGTCCCCAGGCTGACTGGGACCCTCT

p.Ala1169ThrfsTer36

p.A1169Tfs*36

O60885

protein_coding

TCGA-A8-A0A4-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

BRD4

insertion

Nonsense_Mutation

novel

c.4055_4056insACATAGTTGGCATATCTTTGTTTGAAGTTTGTTGGTGGA

p.Ser1351_Asp1352insGluHisSerTrpHisIlePheValTerSerLeuLeuVal

p.S1351_D1352insEHSWHIFV*SLLV

O60885

protein_coding

TCGA-B6-A0I8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

BRD4

insertion

In_Frame_Ins

novel

c.3737_3738insCACAATGGCACTGCTTATCTC

p.Glu1246delinsAspThrMetAlaLeuLeuIleSer

p.E1246delinsDTMALLIS

O60885

protein_coding

TCGA-BH-A0H7-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

BRD4

SNV

Missense_Mutation

novel

c.3767N>A

p.Arg1256Gln

p.R1256Q

O60885

protein_coding

tolerated(0.18)

benign(0.196)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME		Aminocyclopentenone compound 1
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME	inhibitor	178102626
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME		Aminocyclopentenone compound 6
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME	inhibitor	405067321
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME		BIRABRESIB	BIRABRESIB	26976114
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME		CPI-0610
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME		RVX-208	APABETALONE
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME		ALPRAZOLAM	ALPRAZOLAM	22137933
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME	inhibitor	187051820
23476	BRD4	CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME	inhibitor	252166516

Page: 1 2 3 4 5 6 7 8 9